European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Data from the IGNITE4 phase 3 trial supports the use of eravacycline for the treatment of complicated intra-abdominal infections (cIAI), including infections caused by pathogens resistant to other antibiotics.

An outbreak of infections caused by the drug-resistant fungus, Candida auris, in one United Kingdom hospital has been linked to multi-use patient equipment.

Investigational beta-lacatamase inhibitor IMI/REL demonstrates a favorable overall response against certain imipenem-non-susceptible bacterial infections.

Researchers present positive new data from multiple studies of VIBATIV at the 2018 ECCMID conference in Madrid, Spain.